Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carbamazepine + nevirapine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of carbamazepine and nevirapine used to accelerate nevirapine elimination and reduce HIV-1 resistance mutations. Single-dose carbamazepine has been shown to reduce nevirapine-driven HIV mutations, particularly in the context of preventing mother-to-child transmission of HIV. The effect is modulated by individual CYP3A activity, with carbamazepine inducing CYP3A4 to enhance nevirapine metabolism.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseCYP3A4 (Cytochrome P450 3A4)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on carbamazepine + nevirapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carbamazepine + nevirapine.